COLORADO: The daily administration of CBD is associated with sustained symptomatic relief in patients diagnosed with anxiety disorders, according to the results of a case series published in The Permanente Journal.
Investigators at the University of Colorado, Denver and Colorado State University assessed the adjunctive use of low daily doses of CBD (typically 25mg capsules) over a three-month period in a cohort of patients diagnosed with either sleep or anxiety disorders.
Researchers reported that patients experienced a “mild improvement” in sleep scores, and a larger “more sustained response to anxiety.” They also reported that “CBD appears to be better tolerated than routine psychiatric medications.”
Authors acknowledged that the therapeutic doses used in the study were far lower than those typically associated with anxiolytic action in prior clinical trials.
They concluded: “Anxiety scores decreased fairly rapidly, and this decrease was sustained during the study period. … Randomized and controlled trials are needed to provide definitive clinical guidance.”
For more information, contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, “Cannabidiol in anxiety and sleep: A large case series,” appears in The Permanente Journal.